GI Oncology Now Conference Coverage
GI Oncology Now reviews education from ASCO GI 2025, featuring the latest advances in the field of GI cancer research.
Coverage of the 2025 ASCO GI Symposium, with a focus on liver cancer
GI Oncology Now reviews education from ASCO GI 2024, featuring the latest advances in the field of GI cancer research.
Coverage of the 2024 ASCO GI Symposium, focusing on liver cancer
The Latest From GI Oncology Now
Suvemcitug, envafolimab, and FOLFIRI may serve as a new second-line treatment option for cold tumors.
KRASG12C inhibitors can have reduced efficacy in patients with alterations in KRAS, EGFR, and other genes.
Complete responders with HCC have prolonged survival and durable disease control even after therapy has been discontinued.
The primary objective of median PFS was significantly longer for patients treated with 177Lu-edotreotide.
The safety profile of the combination was consistent with known profiles, and no new safety findings were observed.
Older patients in their 70s with extrahepatic CCA have a higher rate of choledocholithiasis.
Dr. Cytryn shares insights on the implications of recent data from the DESTINY-Gastric04 and MATTERHORN trials.
Factors including young age and low preoperative PNI were linked to an unfavorable prognosis in high-risk patients with GIST.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.